Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 168

Results For "MP"

9962 News Found

Bayer introduces chemo-free treatment option for advanced prostate cancer in India
News | February 24, 2026

Bayer introduces chemo-free treatment option for advanced prostate cancer in India

Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year


Eris Lifesciences partnership with Natco Pharma for Semaglutide launch in India
News | February 24, 2026

Eris Lifesciences partnership with Natco Pharma for Semaglutide launch in India

The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape


FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment
Drug Approval | February 24, 2026

FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment

In 2025, over 1 million patients accessed Lilly treatments through LillyDirect


biomodal expands multiomic reach with Element Biosciences pact
News | February 24, 2026

biomodal expands multiomic reach with Element Biosciences pact

The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC


Sai Life Sciences to hire 700+ professionals to support expansion
News | February 24, 2026

Sai Life Sciences to hire 700+ professionals to support expansion

One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree


ImmunityBio partners with Middle East giants to launch ANKTIVA for cancer patients
Biopharma | February 24, 2026

ImmunityBio partners with Middle East giants to launch ANKTIVA for cancer patients

To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia


UK pours £20 million into cutting?edge tech to tackle drug & alcohol addiction
News | February 24, 2026

UK pours £20 million into cutting?edge tech to tackle drug & alcohol addiction

The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences


Ultragenyx bags FDA priority review for groundbreaking GSDIa gene therapy
Drug Approval | February 24, 2026

Ultragenyx bags FDA priority review for groundbreaking GSDIa gene therapy

If approved, DTX401 would be the first treatment to address the disease at its root cause


Novo Nordisk’s
Clinical Trials | February 24, 2026

Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks

UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies


FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL
Drug Approval | February 23, 2026

FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL

The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years